These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24002090)

  • 41. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
    Schafer JJ; Short WR
    Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
    Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.
    Sluis-Cremer N; Huber KD; Brumme CJ; Harrigan PR
    Antimicrob Agents Chemother; 2014; 58(4):2430-3. PubMed ID: 24419343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
    Selhorst P; Vazquez AC; Terrazas-Aranda K; Michiels J; Vereecken K; Heyndrickx L; Weber J; Quiñones-Mateu ME; Ariën KK; Vanham G
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1403-13. PubMed ID: 21282453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
    Xu HT; Quan Y; Schader SM; Oliveira M; Bar-Magen T; Wainberg MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2401-8. PubMed ID: 20308384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
    Wang J; Liang H; Bacheler L; Wu H; Deriziotis K; Demeter LM; Dykes C
    Virology; 2010 Jul; 402(2):228-37. PubMed ID: 20399480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.
    Xu HT; Oliveira M; Asahchop EL; McCallum M; Quashie PK; Han Y; Quan Y; Wainberg MA
    J Virol; 2012 Dec; 86(23):12983-90. PubMed ID: 22993165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
    Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.
    Sluis-Cremer N; Jordan MR; Huber K; Wallis CL; Bertagnolio S; Mellors JW; Parkin NT; Harrigan PR
    Antiviral Res; 2014 Jul; 107():31-4. PubMed ID: 24746459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
    Johnson BC; Pauly GT; Rai G; Patel D; Bauman JD; Baker HL; Das K; Schneider JP; Maloney DJ; Arnold E; Thomas CJ; Hughes SH
    Retrovirology; 2012 Dec; 9():99. PubMed ID: 23217210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
    Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
    Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
    Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
    Rattanabunyong S; Choengpanya K; Suwattanasophon C; Kiriwan D; Wolschann P; Lamtha T; Shaikh AR; Rattanasrisomporn J; Choowongkomon K
    J Vet Sci; 2023 Sep; 24(5):e67. PubMed ID: 38031646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
    Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.